Opioid Therapy: Adverse Effects Including Addiction

SPEC - Essentials of Pain Medicine and Regional Anesthesia (Reprint)

Volumn , Issue , 2005, Pages 113-123

  Mahajan, Gagan ^a   Wilsey, Barth ^a   Fishman, Scott M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34147094407     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06651-1.50017-4     Document Type: Chapter

References (62)

1. Friedman JD, Dello Buono FA Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001, 35:85-91.
2. Klaschik E, Nauck F, Ostgathe C Constipation - Modern laxative therapy. Support Care Cancer 2003, 11:679-685.
3. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001, 322:1154-1158.
4. Wilsey BL, Mahajan G, Fishman SM Opioid therapy in chronic non-malignant pain. Drugs for Pain 2003, 119-132. Hanley & Belfus, Philadelphia. H.S. Smith (Ed.).
5. Choi YS, Billings JA Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002, 24:71-90.
6. De Ponti F Methylnaltrexone progenics. Curr Opin Investig Drugs 2002, 3:614-620.
7. Sykes NP Oral naloxone in opioid-associated constipation. Lancet 1991, 337:1475.
8. Robinson BA, Johansson L, Shaw J Oral naloxone in opioid-associated constipation. Lancet 1991, 338:581-582.
9. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 1992, 52:90-95.
10. Latasch L, Zimmermann M, Eberhardt B, Jurna I [Treatment of morphine-induced constipation with oral naloxone]. Anaesthesist 1997, 46:191-194.
11. Murphy DB, Sutton JA, Prescott LF, Murphy MB Opioid-induced delay in gastric emptying: A peripheral mechanism in humans. Anesthesiology 1997, 87:765-770.
12. Gan TJ, Ginsberg B, Glass PS, et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997, 87:1075-1081.
13. Yuan CS, Foss JF, O'Connor M, et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998, 52:161-165.
14. Slatkin NE, Rhiner M, Bolton TM Donepezil in the treatment of opioid-induced sedation: Report of six cases. J Pain Symptom Manage 2001, 21:425-438.
15. Clinical Practice Guideline for the Management of Cancer Pain 1994, 9:61-64. Pharmacologic Management, Agency for Health Care Policy and Research.
16. Rozans M, Dreisbach A, Lertora JJ, Kahn MJ Palliative uses of methylphenidate in patients with cancer: A review. J Clin Oncol 2002, 20:335-339.
17. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: An anti-narcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997, 42:1181-1183.
18. Webster L, Andrews M, Stoddard G Modafinil treatment of opioid-induced sedation. Pain Med 2003, 4:135-140.
19. Jasinski DR An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000, 14:53-60.
20. Jasinski DR, Kovacevic-Ristanovic R Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000, 23:149-156.
21. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: A pilot study. J Pain Symptom Manage 2003, 26:1049-1054.
22. Bouillon T, Bruhn J, Roepcke H, Hoeft A Opioid-induced respiratory depression is associated with increased tidal volume variability. Eur J Anaesthesiol 2003, 20:127-133.
23. Anwari JS, Iqbal S Antihistamines and potentiation of opioid induced sedation and respiratory depression. Anaesthesia 2003, 58:494-495.
24. Kyriakides K, Hussain SK, Hobbs GJ Management of opioid-induced pruritus: A role for 5-HT3 antagonists?. Br J Anaesth 1999, 82:439-441.
25. Szarvas S, Harmon D, Murphy D Neuraxial opioid-induced pruritus: A review. J Clin Anesth 2003, 15:234-239.
26. Kjellberg F, Tramer MR Pharmacological control of opioid-induced pruritus: A quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001, 18:346-357.
27. Larijani GE, Goldberg ME, Rogers KH Treatment of opioid-induced pruritus with ondansetron: Report of four patients. Pharmacotherapy 1996, 16:958-960.
28. Raderer M, Muller C, Scheithauer W Ondansetron for pruritus due to cholestasis. N Engl J Med 1994, 330:1540.
29. Krajnik M, Zylicz Z Understanding pruritus in systemic disease. J Pain Symptom Manage 2001, 21:151-168.
30. Horta ML, Ramos L, Goncalves ZR The inhibition of epidural morphine-induced pruritus by epidural droperidol. Anesth Analg 2000, 90:638-641.
31. Yeh HM, Chen LK, Lin CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2000, 91:172-175.
32. Torn K, Tuominen M, Tarkkila P, Lindgren L Effects of sub-hypnotic doses of propofol on the side effects of intrathecal morphine. Br J Anaesth 1994, 73:411-412.
33. Colbert S, O'Hanlon DM, Chambers F, Moriarty DC The effect of intravenous tenoxicam on pruritus in patients receiving epidural fentanyl. Anaesthesia 1999, 54:76-80.
34. Colbert S, O'Hanlon DM, Galvin S, et al. The effect of rectal diclofenac on pruritus in patients receiving intrathecal morphine. Anaesthesia 1999, 54:948-952.
35. Fishbain DA, Rosomoff HL, Rosomoff RS Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992, 8:77-85.
36. Hoffmann NG, Olofsson O, Salen B, Wickstrom L Prevalence of abuse and dependency in chronic pain patients. Int J Addict 1995, 30:919-927.
37. Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003, 289:2370-2378.
38. Passik SD Responding rationally to recent report of abuse/diversion of Oxycontin. J Pain Symptom Manage 2001, 21:359.
39. Joranson DE, Ryan KM, Gilson AM, Dahl JL Trends in medical use and abuse of opioid analgesics. JAMA 2000, 283:1710-1714.
40. Definitions related to the use of opioids for the treatment of chronic pain. A consensus document from the American Academy of Pain Medicine 2001, Addiction LCoPa, the American Pain Society, and the American Society of Addiction Medicine, www.ampainsoc.org.
41. Gilson AM, Joranson DE US policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain 2002, 18:S91-S98.
42. Code of Federal Regulations 58FR 37507-37508 July 12, 1993.
43. Code of Federal Regulations 42 Section 8.12. October 1, 2002.
44. Diagnostic aand Statistical Manual of Mental Disorders: DSM-IV 1994, American Psychiatric Association, American Psychiatric Publishing Inc., Arlington. 4th ed.
45. Portenoy RK, Dole V, Joseph H, et al. Pain management and chemical dependency. Evolving perspectives. JAMA 1997, 278:592-593.
46. Weissman DE, Haddox JD Opioid pseudoaddiction - An iatrogenic syndrome. Pain 1989, 36:363-366.
47. Scimeca MM, Savage SR, Portenoy R, Lowinson J Treatment of pain in methadone-maintained patients. Mt Sinai J Med 2000, 67:412-422.
48. Dunbar SA, Katz NP Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: Report of 20 cases. J Pain Symptom Manage 1996, 11:163-171.
49. Savage S Management of acute pain, chronic pain and cancer pain in the addicted patient. Principles of Addiction Medicine, vol sec VIII 1994, 4. American Society of Addiction Medicine (ASAM), Chevy Chase, MD. N. Miller (Ed.).
50. Merrill JO, Rhodes LA, Deyo RA, et al. Mutual mistrust in the medical care of drug users: The keys to the "narc" cabinet. J Gen Intern Med 2002, 17:327-333.
51. Mendelson D Legal liability for pain management involving opioid medication: An American perspective. J Law Med 2002, 10:145-154.
52. Fleischman J, Galler D Prescription for addiction?. Adv Nurse Pract 2001, 9:27.
53. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend 2003, 69:215-232.
54. Wasserman S States respond to growing abuse of painkiller. State Legis 2001, 27:33-34.
55. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003, 97:1097-1102. table of contents.
56. Clark JD Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage 2002, 23:131-137.
57. Potter M, Schafer S, Gonzalez-Mendez E, et al. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract 2001, 50:145-151.
58. McCarberg BH, Barkin RL Long-acting opioids for chronic pain: Pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001, 8:181-186.
59. Heit HA The truth about pain management: The difference between a pain patient and an addicted patient. Eur J Pain 2001, 5(Suppl A):27-29.
60. Mahoney ND, Devine JE, Angres D Multidisciplinary treatment of benign chronic pain syndrome in substance abusing patients. Curr Rev Pain 1999, 3:321-331.
61. Fishman SM, Bandman TB, Edwards A, Borsook D The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999, 18:27-37.
62. Sees KL, Clark HW Opioid use in the treatment of chronic pain: Assessment of addiction. J Pain Symptom Manage 1993, 8:257-264.